Oxazoline and isoxazoline derivatives as CRAC modulators

A method of managing asthma, in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a compound of Formula (I):

• wherein:
• R1, which may be same or different at each occurrence, is independently selected from halogen, alkyl, haloalkyl, alkoxy, and cycloalkyl;
• R2, is selected from hydrogen, halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, and cycloalkyl;
• R is alkyl;
• and
• p is an integer ranging from 0 to 2, both inclusive;
• or a pharmaceutically acceptable salt thereof or stereoisomers thereof.

A method of managing asthma, in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a compound selected from:

• 2,6-Difluoro-N-(2′-methyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• N-(5′-(4-Ethyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2′-methyl-[1,1′-biphenyl]-4-yl)-2,6-difluorobenzamide,
• 2,6-Difluoro-N-(2′-methyl-5′-(5-oxo-4-propyl-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• N-(2′-Ethyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-2,6-difluorobenzamide,
• 2-Chloro-N-(2′-ethyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-6-fluorobenzamide,
• N-(2′-Ethyl-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-2-fluoro-6-methylbenzamide,
• 2,6-Difluoro-N-(2′-methoxy-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• 2-Chloro-6-fluoro-N-(2′-methoxy-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• 2-Fluoro-N-(2′-methoxy-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-6-methylbenzamide,
• 4-Ethyl-N-(2′-methoxy-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• N-(2′-(Difluoromethoxy)-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-2,6-difluorobenzamide,
• N-(2′-Chloro-5′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-2,6-difluorobenzamide,
• 2,6-Difluoro-N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide,
• 2-Chloro-6-fluoro-N-(2′-methyl-3′-(4-methyl-5-oxo-4, 5 -dihydro- 1,3 ,4-oxadiazol-2-yl)-[1,1-biphenyl]-4-yl)benzamide, and
• N-(2′-ethyl-3′-(4-methyl-5 -oxo-4, 5 -dihydro- 1, 3 ,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-2,6-difluorobenzamide,
• or pharmaceutically acceptable salt thereof.